Erythromycin is a drug active against gram positive bacteria such as Lactococcus garvieae, a pathogen responsible for an important disease that may cause a substantial decrease in rainbow trout production, the most raised species in Italy. In literature, studies regarding the kinetics behavior of erythromycin in fish are limited. This study was thus aimed to evaluate the pharmacokinetics of erythromycin in rainbow trout after a single oral treatment with 75 mg kg-1 b.w., and the residue depletion after multiple oral administration of 75 mg kg-1 b.w. day-1 for 10 days. Blood concentrations of erythromycin increased up to 20.24±13.32 μg mL-1 at 6h, then decreased to 5.97±3.89 μg mL-1 at 24h. T>MIC and AUC/MIC are both PK/PD parameters predictors of ERY efficacy and the obtained data allow us to hypothesize that a dosage of 75 mg kg-1 b.w. day-1 could be able to contrast the lactococcosis in trout. Regarding the study of erythromycin depletion, a rapid elimination was observed in tissue (muscle plus adherent skin): actually, the concentrations were below the limit of quantification in all samples (except two) the 10th day post treatment. Erythromycin is not licensed in Europe for the use in aquaculture and its use is possible only by off-label prescription with a precautionary withdrawal time of 500°C/day as established by Directive 2004/28/EC. From the obtained data, a withdrawal time of 8.90 days was calculated, corresponding, in our experimental conditions, to 117.5 °C/day, a value significantly lower than that established by the European directive
Pharmacokinetics and residue depletion of erythromycin in rainbow trout, Oncorhynchus mykiss (Walbaum)
DI SALVO, Alessandra;DELLA ROCCA, Giorgia;PELLEGRINO, Roberto Maria
2013
Abstract
Erythromycin is a drug active against gram positive bacteria such as Lactococcus garvieae, a pathogen responsible for an important disease that may cause a substantial decrease in rainbow trout production, the most raised species in Italy. In literature, studies regarding the kinetics behavior of erythromycin in fish are limited. This study was thus aimed to evaluate the pharmacokinetics of erythromycin in rainbow trout after a single oral treatment with 75 mg kg-1 b.w., and the residue depletion after multiple oral administration of 75 mg kg-1 b.w. day-1 for 10 days. Blood concentrations of erythromycin increased up to 20.24±13.32 μg mL-1 at 6h, then decreased to 5.97±3.89 μg mL-1 at 24h. T>MIC and AUC/MIC are both PK/PD parameters predictors of ERY efficacy and the obtained data allow us to hypothesize that a dosage of 75 mg kg-1 b.w. day-1 could be able to contrast the lactococcosis in trout. Regarding the study of erythromycin depletion, a rapid elimination was observed in tissue (muscle plus adherent skin): actually, the concentrations were below the limit of quantification in all samples (except two) the 10th day post treatment. Erythromycin is not licensed in Europe for the use in aquaculture and its use is possible only by off-label prescription with a precautionary withdrawal time of 500°C/day as established by Directive 2004/28/EC. From the obtained data, a withdrawal time of 8.90 days was calculated, corresponding, in our experimental conditions, to 117.5 °C/day, a value significantly lower than that established by the European directiveI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
